| ²é¿´: 621 | »Ø¸´: 2 | |||
adslyeÒø³æ (ÕýʽдÊÖ)
|
[ÇóÖú]
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
|
|
This variation seeks approval for changes to Methotrexate Injection 25 mg/mL and 100 mg/mL,£¨ involving a minor amendment in the drug substance manufacturing process, employed by Fermion OY, concerning a change in the final isolated intermediate.£© ¾ä×Ó·ÖÁ½²¿·Ö£¬À¨ºÅÄÚµÄΪһ²¿·Ö£¬½²µÄÊǵ×ÎïºÏ³ÉÖеÄÒ»´¦Ð޸ġ£Ã»ÓÐÉÏÏÂÎÄ£¬¹Ê·Ò빩²Î¿¼£º 1¡¢This variation²»ºÃ·Ò룬×ÜÖ®¾ÍÊÇijÖָı䡣 2¡¢ changes ²»ºÃ·Ò룬×Ü֮ĿµÄÊÇ»ñµÃÕâ¸öchangeµÄÅú¸´¡£ 3¡¢ involvingÕâ¸ö²åÈëÓïÓ¦¸ÃÖ¸µÄÊÇ changesµÄÒ»²¿·Ö£¬ÒÔ¼°ºóÃæ½ÓµÄ¶¼ÊÇÔÚ½«»¯Ñ§ºÏ³É£¬ÓëÇ°ÃæµÄÄÚÈÝÃ÷ÏÔ²»Í¬ÁË¡£ 4¡¢ isolated intermediate ·ÖÀëÖмäÌ壬ҩ»¯×¨ÓÐÃû´Ê ½ö¹©²Î¿¼£º Õâ¸ö±ä»¯£¬ÎªÁËÄܹ»»ñ׼ʹÓüװ±µûßÊ×¢Éä¼Á25 mg/mLºÍ100 mg/mL£¬ÒÔ¼°°üÀ¨ Fermion OY½øÐеÄÒ©Îïµ×ÎïÉú²úÁ÷³ÌÖеÄÒ»´¦Î¢Ð¡Ð޸ģ¬Õâ¸öÐÞ¸ÄÊÇÕë¶Ô×îÖյķÖÀëÖмäÌå¡£ |
» ²ÂÄãϲ»¶
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8.O.55.1.O.54,¿ÆÄ¿ÆëÈ«,¿ÉÙ¤¼±
ÒѾÓÐ5È˻ظ´
ÎÒ¾ÍÊÇÉêÇëÒ»¸öÃæÉÏÏîÄ¿¶øÒÑ£¬ÕâÆÀÉóÒâ¼ûÊǰ´ÕÕ½ÜÇàµÄÌõ¼þÆÀµÄ°É£¿
ÒѾÓÐ4È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8.O.55.1.O.54,¿ÆÄ¿ÆëÈ«,¿ÉÙ¤¼±
ÒѾÓÐ4È˻ظ´
ÊÛSCI-T0PÎÄÕ£¬ÎÒ:8O.5.5.1.O.54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ4È˻ظ´
ÊÛSCIÎÄÕ£¬ÎÒ:8O.5.5.1O.54,¿ÆÄ¿È«,¿ÉÊ®¼±
ÒѾÓÐ3È˻ظ´
ÓжàÉÙÈËÊǽñÌì²éϵͳ֪µÀ½á¹ûµÄ£¿
ÒѾÓÐ18È˻ظ´
¹ú×ÔÈ»ÆÀÉóÒâ¼û
ÒѾÓÐ15È˻ظ´
Ϊʲô×ÊÖúÊý¸÷´ó¸ßУ¶¼´´Ð¸ߣ¬×Ô¼ºÉêÇëÔõô¾ÍÕâôÄÑ
ÒѾÓÐ13È˻ظ´
¹ú×ÔÈ»ÃæÉϸ´ÅÌ~»¶ÓÌÖÂÛ
ÒѾÓÐ14È˻ظ´
ϵͳ²é²»µ½
ÒѾÓÐ11È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
´ó¼Ò°ïæ·ÒëÒ»¾ä»°
ÒѾÓÐ3È˻ظ´
·ÒëÒ»¾ä»° ÐÂÒ©Ñз¢ ÑéÖ¤·½°¸·½Ãæ
ÒѾÓÐ6È˻ظ´
ÇóÖú·ÒëÒ»¾ä»°
ÒѾÓÐ4È˻ظ´
·ÒëÒ»¾ä»°£¬ÀÏÊǸоõ·Òë²»³öÄǸöÒâ˼£¡
ÒѾÓÐ1È˻ظ´
ÂÛÎÄÕªÒª·Òë Ò»¾ä»° ·Ç³£¸Ðл
ÒѾÓÐ1È˻ظ´
ÔÚÒ©ÎﻯѧÖÐ PK profile Ôõô·Òë ÊÇʲôÒâ˼°¡
ÒѾÓÐ11È˻ظ´
°ïæ·ÒëÒ»¾ä»° »¯Ñ§·½ÃæµÄ ллŶ
ÒѾÓÐ1È˻ظ´
°ïæ·ÒëÒ»¾ä»°
ÒѾÓÐ1È˻ظ´
ÇóÖúÒ»¾ä»°µÄ·Ò룬 ÉúÎïÒ½Ò©·½ÃæµÄ
ÒѾÓÐ4È˻ظ´
Ò»¾ä»°ÖÐÒëÓ¢£¬ÉúÎïרҵ Õæ³Ï¸Ð¼¤ÁË
ÒѾÓÐ1È˻ظ´
Ò»¾ä»°·Ò룬¹ØÓÚ»¯Ñ§¼ü·½ÃæµÄ
ÒѾÓÐ3È˻ظ´
°ïæ·ÒëÒ»¾ä»°
ÒѾÓÐ2È˻ظ´
·ÒëÒ»¾ä»°£¬Ð»Ð»
ÒѾÓÐ2È˻ظ´
·ÒëÒ»¾ä»°£¨objectives£©
ÒѾÓÐ6È˻ظ´
ÇóÖú·ÒëÒ»¾ä»°
ÒѾÓÐ2È˻ظ´
Çó·ÒëÒ»¾ä»°£¡ ÔÚÏßµÈ
ÒѾÓÐ3È˻ظ´









»Ø¸´´ËÂ¥
30